Sinomab Bioscience is focused on the development of innovative biopharmaceuticals, particularly in the realm of immunological diseases. Their flagship product, SM03 (Suciraslimab), is a first-in-class anti-CD22 monoclonal antibody designed for the treatment of rheumatoid arthritis (RA) and other related conditions. This product has demonstrated a novel mechanism of action that sets it apart from existing therapies, having successfully met its primary endpoint in a Phase III clinical study in China. The company is also advancing its biologics license application (BLA) for SM03, which has undergone necessary inspections for compliance with Good Manufacturing Practice (GMP) standards.

In addition to SM03, Sinomab's product pipeline includes several other promising candidates. SM17 is a humanized IgG4-κ monoclonal antibody targeting the IL-25 receptor, aimed at treating various allergic and autoimmune diseases. SN1011, a third-generation BTK inhibitor, is designed for long-term treatment of systemic lupus erythematosus and other neuro-immunological disorders, showcasing high selectivity and a favorable safety profile. Furthermore, the company is developing SM09, a humanized anti-CD20 antibody with a unique target epitope, and SM06, a second-generation anti-CD22 antibody that utilizes proprietary framework-patching technology to enhance its safety and efficacy. These advancements reflect Sinomab's commitment to addressing significant unmet medical needs in the biopharmaceutical landscape.

China

SinoMab BioScience Limited (stock code: 3681.HK) is a Hong Kong based clinical-phase biopharmaceutical company focus on the development of novel and high-value recombinant therapeutic proteins for treating various life-threatening and debilitating diseases in human.

Sinomab Bioscience

Company Details